MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ccd.28535

Медицинская библиотека · Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2019

A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.

Sullivan Alexander E, Nanna Michael G, Rao Sunil V, Cantrell Sarah, Gibson C Michael, Verheugt Freek W A, Peterson Eric D, Lopes Renato D, Alexander John H, Granger Christopher B, Yee Megan K, Kong David F

СтатьяПоддержка NIH: внешняя программаСистематический обзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Prior randomized controlled trials (RCT) evaluating the optimal antithrombotic therapies for patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) have not been powered to evaluate ischemic outcomes. We compared double therapy with oral anticoagulation (OAC) and a P2Y12 inhibitor to triple therapy with an OAC + dual antiplatelet therapy in patients with AF requiring PCI.

METHODS

Using PRISMA guidelines, we searched for RCTs including patients with AF as an indication for OAC and undergoing PCI or medical management of acute coronary syndrome. The results were pooled using fixed-effects and random-effects models to estimate the overall effect of double therapy versus triple therapy on ischemic and bleeding outcomes.

RESULTS

We identified four RCTs, comprising 10,238 patients (5,498 double therapy, 4,740 triple therapy). Trial-reported major adverse cardiovascular events were similar between double therapy and triple therapy (fixed effect model OR 1.09, 95% CI 0.94-1.26). However, stent thrombosis (61/5,496 double therapy vs. 33/4738 triple therapy; fixed effect model OR 1.57, 95% CI 1.02-2.40; number needed to treat with triple therapy = 242) favored triple therapy. Bleeding outcomes were less frequent with double therapy (746/5470 vs. 950/4710; fixed effect model OR 0.59, 95% CI 0.53-0.65; number needed to harm with triple therapy = 16), but with significant heterogeneity (Q = 8.33, p = .04; I2 = 64%), as were intracranial hemorrhages (19/5470 vs. 30/4710; fixed effect model OR 0.54, 95% CI 0.31-0.96).

CONCLUSIONS

Double therapy in patients with AF requiring OAC following PCI or Acute coronary syndrome has a significantly better safety profile than triple therapy but may be associated with a modest increased risk of stent thrombosis.

Для цитирования: Sullivan Alexander E, Nanna Michael G, Rao Sunil V, Cantrell Sarah, Gibson C Michael, Verheugt Freek W A, Peterson Eric D, Lopes Renato D, Alexander John H, Granger Christopher B, Yee Megan K, Kong David F. A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. 2019. DOI: 10.1002/ccd.28535.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.